Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament.

Abstract: A water- and oxygen-occlusive pack is described. The pack encloses an inert atmosphere containing medicinal tablets, wherein the tablets contain buprenorphine or a salt or ester thereof.

Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to or reaching the plasma of a patient is in the range 22.6:1 to 40:1. The analgesic action of the buprenorphine is potentiated by the low dose of nalmefene. Also provided are a method of treatment of pain and the use of nalmefene and buprenorphine for the manufacture of a medicament.

Abstract: A composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone delivered to or reaching the plasma of a patient is in the range of from 7.5:1 to 12.4:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, which also serves to reduce the likelihood of abuse of the composition by drug addicts. Also provided are a method of treatment of pain and the use of naloxone and buprenorphine for the manufacture of a medicament.

Abstract: A water- and oxygen-occlusive pack is described. The pack encloses an inert atmosphere containing medicinal tablets, wherein the tablets contain buprenorphine or a salt or ester thereof.

Abstract: There is provided a composition for the treatment of pain in human patients wherein said composition comprises buprenorphine to naloxone in a ratio by weight of from 2.1:1 to 8:1, the amount of buprenorphine and naloxone being suitable to provide analgesia, the composition being in a transdermal or transmucosal dosage form. Also provided are an associated method and use.

Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to or reaching the plasma of a patient is in the range 22.6:1 to 40:1. The analgesic action of the buprenorphine is potentiated by the low dose of nalmefene. Also provided are a method of treatment of pain and the use of nalmefene and buprenorphine for the manufacture of a medicament.

Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament.

Abstract: A pack contains medicinal tablets containing a phenothiazine derivative, prochlorperazine maleate, as active ingredient. The tablets are protected from damage by water. The pack is suitably a water-occlusive blister pack.